To piggy back on this, it is my belief that management and the board knew of RP’s interest long before the general public did. Knowing that there was a chance with Leronlimab having an application in cancer likely took deals off the table long ago. As retail investors, we obviously weren’t privileged with that info and often wondered what the heck was going on.
News 
Market Data 
Discover 
